Condition
Hepatic Impairment (HI)
Total Trials
3
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Recruiting2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06841315Phase 1Completed
A Varegacestat Hepatic Impairment Study
NCT07324616Phase 1RecruitingPrimary
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
NCT06442436Phase 1RecruitingPrimary
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Showing all 3 trials